Proprietary porous-particle technology permits the formulation of long-acting muscarinic antagonists , long-acting @-agonists , and a combination of both in hydrofluoroalkane ( HFA ) MDIs , providing a solution to formulation challenges inherent to the development of HFA MDIs , which have contributed to the development of dry-powder inhalers .